http://purl.org/np/RAb12Y2zfCJtlQDNH3EJK-Nts35cNjiOTpWtifGDHor6s#Head http://purl.org/np/RAb12Y2zfCJtlQDNH3EJK-Nts35cNjiOTpWtifGDHor6s http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RAb12Y2zfCJtlQDNH3EJK-Nts35cNjiOTpWtifGDHor6s#assertion http://purl.org/np/RAb12Y2zfCJtlQDNH3EJK-Nts35cNjiOTpWtifGDHor6s http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RAb12Y2zfCJtlQDNH3EJK-Nts35cNjiOTpWtifGDHor6s#provenance http://purl.org/np/RAb12Y2zfCJtlQDNH3EJK-Nts35cNjiOTpWtifGDHor6s http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RAb12Y2zfCJtlQDNH3EJK-Nts35cNjiOTpWtifGDHor6s#pubinfo http://purl.org/np/RAb12Y2zfCJtlQDNH3EJK-Nts35cNjiOTpWtifGDHor6s http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RAb12Y2zfCJtlQDNH3EJK-Nts35cNjiOTpWtifGDHor6s#assertion http://purl.obolibrary.org/obo/DOID_10763 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RAb12Y2zfCJtlQDNH3EJK-Nts35cNjiOTpWtifGDHor6s#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_10763 http://purl.org/np/RAb12Y2zfCJtlQDNH3EJK-Nts35cNjiOTpWtifGDHor6s#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RAb12Y2zfCJtlQDNH3EJK-Nts35cNjiOTpWtifGDHor6s#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB09026 http://purl.org/np/RAb12Y2zfCJtlQDNH3EJK-Nts35cNjiOTpWtifGDHor6s#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RAb12Y2zfCJtlQDNH3EJK-Nts35cNjiOTpWtifGDHor6s#association http://www.w3.org/2000/01/rdf-schema#label tekturna is a renin inhibitor ri indicated for the treatment of hypertension in adults and children 6 years of age and older to lower blood pressure 1 1 lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events primarily strokes and myocardial infarctions tekturna is indicated for the treatment of hypertension in adults and children 6 years of age and older to lower blood pressure lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events primarily strokes and myocardial infarctions these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes there are no controlled trials demonstrating risk reduction with tekturna control of high blood pressure should be part of comprehensive cardiovascular risk management including as appropriate lipid control diabetes management antithrombotic therapy smoking cessation exercise and limited sodium intake many patients will require more than 1 drug to achieve blood pressure goals for specific advice on goals and management see published guidelines such as those of the national high blood pressure education program s joint national committee on prevention detection evaluation and treatment of high blood pressure jnc numerous antihypertensive drugs from a variety of pharmacologic classes and with different mechanisms of action have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality and it can be concluded that it is blood pressure reduction and not some other pharmacologic property of the drugs that is largely responsible for those benefits the largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke but reductions in myocardial infarction and cardiovascular mortality have also been seen regularly elevated systolic or diastolic pressure causes increased cardiovascular risk and the absolute risk increase per mmhg is greater at higher blood pressures so that even modest reductions of severe hypertension can provide substantial benefit relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk so the absolute benefit is greater in patients who are at higher risk independent of their hypertension e g patients with diabetes or hyperlipidemia and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal some antihypertensive drugs have smaller blood pressure effects as monotherapy in black patients and many antihypertensive drugs have additional approved indications and effects e g on angina heart failure or diabetic kidney disease these considerations may guide selection of therapy http://purl.org/np/RAb12Y2zfCJtlQDNH3EJK-Nts35cNjiOTpWtifGDHor6s#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RAb12Y2zfCJtlQDNH3EJK-Nts35cNjiOTpWtifGDHor6s#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RAb12Y2zfCJtlQDNH3EJK-Nts35cNjiOTpWtifGDHor6s#association https://w3id.org/biolink/vocab/relation https://schema.org/TreatmentIndication https://identifiers.org/drugbank:DB09026 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RAb12Y2zfCJtlQDNH3EJK-Nts35cNjiOTpWtifGDHor6s#provenance http://purl.org/np/RAb12Y2zfCJtlQDNH3EJK-Nts35cNjiOTpWtifGDHor6s#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAb12Y2zfCJtlQDNH3EJK-Nts35cNjiOTpWtifGDHor6s#pubinfo http://purl.org/np/RAb12Y2zfCJtlQDNH3EJK-Nts35cNjiOTpWtifGDHor6s#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RAb12Y2zfCJtlQDNH3EJK-Nts35cNjiOTpWtifGDHor6s#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RAb12Y2zfCJtlQDNH3EJK-Nts35cNjiOTpWtifGDHor6s#sig http://purl.org/nanopub/x/hasSignature RIbsDW7v08dGSq4EJ5/jXFuGMg2jOajjpNBz76UNLJOWatldA4xflMnXCKjmFH3maF/+0vqy3dMarpnC/Uflp67RsC5S4VNohrAKIa17+pFA3te9DHgak2Gd/dkMRltmhax1t8HoaX+JFs7Dk+L8I7bOiVqIY4DY03aDJyQo7NA= http://purl.org/np/RAb12Y2zfCJtlQDNH3EJK-Nts35cNjiOTpWtifGDHor6s#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RAb12Y2zfCJtlQDNH3EJK-Nts35cNjiOTpWtifGDHor6s http://purl.org/np/RAb12Y2zfCJtlQDNH3EJK-Nts35cNjiOTpWtifGDHor6s http://purl.org/dc/terms/created 2021-06-13T12:06:16.135+02:00 http://purl.org/np/RAb12Y2zfCJtlQDNH3EJK-Nts35cNjiOTpWtifGDHor6s http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAb12Y2zfCJtlQDNH3EJK-Nts35cNjiOTpWtifGDHor6s https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RAb12Y2zfCJtlQDNH3EJK-Nts35cNjiOTpWtifGDHor6s https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RAb12Y2zfCJtlQDNH3EJK-Nts35cNjiOTpWtifGDHor6s https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs